Takeda expands COVID-19 vaccine supply with Moderna, Japan

By The Science Advisory Board staff writers

October 29, 2020 -- Takeda Pharmaceutical will import and distribute 50 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, starting in the first half of 2021, pending licensure in Japan, as part of a three-way agreement with Takeda, Moderna, and the government of Japan.

This announcement follows the establishment of Takeda's manufacturing capabilities to produce Novavax' COVID-19 vaccine candidate in its Japan-based facilities. Takeda's efforts to bring Moderna's and Novavax' COVID-19 vaccine candidates to Japan are supported by the Ministry of Health, Labour, and Welfare and the Japan Agency for Medical Research and Development.

Under the terms of the agreement, Takeda will be responsible for securing the necessary regulatory approvals prior to distributing the 50 million doses in Japan. Moderna will provide the finished product and will support Takeda with its development and regulatory efforts.

Elektrofi, Takeda partner to advance plasma protein therapeutics
Biotechnology firm Elektrofi and Takeda Pharmaceuticals have partnered to advance high-concentration, low-viscosity protein therapeutics.
Takeda opens new cell therapy manufacturing facility
Takeda Pharmaceuticals said it has opened a new 24,000-sq-ft research and development (R&D) cell therapy manufacturing facility at its R&D headquarters...
Moderna to potentially supply Japan with 40M doses of COVID-19 vaccine
Moderna is in discussion with the Ministry of Health, Labour, and Welfare of Japan to potentially purchase 40 million or more doses of its messenger...
Novavax licenses COVID-19 vaccine to Takeda in Japan
Novavax and Takeda Pharmaceutical have formed a partnership for the development, manufacturing, and commercialization in Japan of NVX-CoV2373, Novavax's...

Copyright © 2020 scienceboard.net

Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter